Transforming growth factor β1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells

[1]  F. Orr,et al.  Human Metastatic Prostate PC3 Cell Lines Degrade Bone Using Matrix Metalloproteinases , 1998, Invasion and Metastasis.

[2]  A. Lipton.  Bisphosphonates and breast carcinoma , 1997, Cancer.

[3]  C. Arteaga,et al.  Predominant cytosolic localization of type II transforming growth factor beta receptors in human breast carcinoma cells. , 1997, Cancer research.

[4]  C. Brinckerhoff,et al.  The AP-1 site and MMP gene regulation: what is all the fuss about? , 1997, Matrix biology : journal of the International Society for Matrix Biology.

[5]  E. Canalis,et al.  Transforming growth factor β1 inhibits collagenase 3 expression by transcriptional and post‐transcriptional mechanisms in osteoblast cultures , 1997 .

[6]  Paul J. Williams,et al.  E-cadherin expression in human breast cancer cells suppresses the development of osteolytic bone metastases in an experimental metastasis model. , 1996, Cancer research.

[7]  S. Saga,et al.  Involvement of transforming growth factor beta1 in autocrine enhancement of gelatinase B secretion by murine metastatic colon carcinoma cells. , 1996, Cancer research.

[8]  P. Atadja,et al.  Differential effects of transforming growth factor-β1 on the expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in young and old human fibroblasts , 1996, Experimental Gerontology.

[9]  M. Granick,et al.  Thrombospondin and transforming growth factor‐beta 1 increase expression of urokinase‐type plasminogen activator and plasminogen activator inhibitor‐1 in human MDA‐MB‐231 breast cancer cells , 1995, Cancer.

[10]  P. V. D. Saag,et al.  Resistance to transforming growth factor beta and activin due to reduced receptor expression in human breast tumor cell lines. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[11]  J. Kanis,et al.  Bone and cancer: pathophysiology and treatment of metastases. , 1995, Bone.

[12]  H. Moses,et al.  Transforming Growth Factor β and Cell Cycle Regulation , 1995 .

[13]  James P. Quigley,et al.  Matrix Metalloproteinase-2 Is an Interstitial Collagenase , 1995, The Journal of Biological Chemistry.

[14]  T. Yoneda,et al.  Facilitation and suppression of bone metastasis. , 1995, Clinical orthopaedics and related research.

[15]  Y. Takeuchi,et al.  Relationship between actions of transforming growth factor (TGF)‐β and cell surface expression of its receptors in clonal osteoblastic cells , 1995, Journal of cellular physiology.

[16]  L. Matrisian.  Matrix Metalloproteinase Gene Expression a , 1994, Annals of the New York Academy of Sciences.

[17]  C. Overall.  Regulation of Tissue Inhibitor of Matrix Metalloproteinase Expression a , 1994, Annals of the New York Academy of Sciences.

[18]  J. Woessner.  The Family of Matrix Metalloproteinasesa , 1994 .

[19]  P. Dijke,et al.  Regulation of the levels of three transforming growth factor β mRNAs by estrogen and their effects on the proliferation of human breast cancer cells , 1993, Molecular and Cellular Endocrinology.

[20]  N. Block,et al.  Secretion of matrix metalloproteinases and their inhibitors (tissue inhibitor of metalloproteinases) by human prostate in explant cultures: reduced tissue inhibitor of metalloproteinase secretion by malignant tissues. , 1993, Cancer research.

[21]  K. Miyazono,et al.  Different signals mediate transforming growth factor-beta 1-induced growth inhibition and extracellular matrix production in prostatic carcinoma cells. , 1993, Experimental cell research.

[22]  R. Pozzatti,et al.  Expression of matrix metalloproteinase genes in transformed rat cell lines of high and low metastatic potential. , 1992, Cancer research.

[23]  L. Chow,et al.  Complete structure of the human gene for 92-kDa type IV collagenase. Divergent regulation of expression for the 92- and 72-kilodalton enzyme genes in HT-1080 cells. , 1991, The Journal of biological chemistry.

[24]  K. Suzuki,et al.  Substrate specificities and activation mechanisms of matrix metalloproteinases. , 1991, Biochemical Society transactions.

[25]  J. Wrana,et al.  Transcriptional and post-transcriptional regulation of 72-kDa gelatinase/type IV collagenase by transforming growth factor-beta 1 in human fibroblasts. Comparisons with collagenase and tissue inhibitor of matrix metalloproteinase gene expression. , 1991, The Journal of biological chemistry.

[26]  G. Wilding,et al.  DNA fluorometric assay in 96-well tissue culture plates using Hoechst 33258 after cell lysis by freezing in distilled water. , 1990, Analytical biochemistry.

[27]  L. Liotta,et al.  Independent expression and cellular processing of Mr 72,000 type IV collagenase and interstitial collagenase in human tumorigenic cell lines. , 1990, Cancer research.

[28]  L. Matrisian,et al.  TGF-β1 inhibition of transin/stromelysin gene expression is mediated through a fos binding sequence , 1990, Cell.

[29]  J. Massagué,et al.  Transforming growth factor-beta switches the pattern of integrins expressed in MG-63 human osteosarcoma cells and causes a selective loss of cell adhesion to laminin. , 1989, The Journal of biological chemistry.

[30]  S. Bates,et al.  Production of and responsiveness to transforming growth factor-beta in normal and oncogene-transformed human mammary epithelial cells. , 1989, Cancer research.

[31]  K. M. Mulder,et al.  Characterization of transforming growth factor-β-resistant subclones isolated from a transforming growth factor-β-sensitive human colon carcinoma cell line , 1988 .

[32]  K. Flanders,et al.  Accumulation, localization, and compartmentation of transforming growth factor beta during endochondral bone development , 1988, The Journal of cell biology.

[33]  S. Kukreja,et al.  Development of skeletal metastasis by human prostate cancer in athymic nude mice , 1988, Clinical & Experimental Metastasis.

[34]  B. Pauli,et al.  Tumor invasion: a consequence of destructive and compositional matrix alterations. , 1988, Human pathology.

[35]  G. Wesolowski,et al.  Characterization of a human osteosarcoma cell line (Saos-2) with osteoblastic properties. , 1987, Cancer research.

[36]  G. Nicolson,et al.  Degradation of basement membrane type IV collagen and lung subendothelial matrix by rat mammary adenocarcinoma cell clones of differing metastatic potentials. , 1987, Cancer research.

[37]  J. Massagué,et al.  Regulation of fibronectin and type I collagen mRNA levels by transforming growth factor-beta. , 1987, The Journal of biological chemistry.

[38]  R. Derynck,et al.  Evidence that transforming growth factor-β is a hormonally regulated negative growth factor in human breast cancer cells , 1987, Cell.

[39]  J. Massagué,et al.  Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix. , 1986, The Journal of biological chemistry.

[40]  L. Liotta,et al.  Expression of collagenase IV (basement membrane collagenase) activity in murine tumor cell hybrids that differ in metastatic potential. , 1985, Journal of the National Cancer Institute.

[41]  D. Tarin,et al.  Correlation of collagenase secretion with metastatic-colonization potential in naturally occurring murine mammary tumours. , 1982, British Journal of Cancer.

[42]  L. Liotta,et al.  Metastatic potential correlates with enzymatic degradation of basement membrane collagen , 1980, Nature.

[43]  E. Dowdle,et al.  Electrophoretic analysis of plasminogen activators in polyacrylamide gels containing sodium dodecyl sulfate and copolymerized substrates. , 1980, Analytical biochemistry.

[44]  J. Lechner,et al.  Establishment and characterization of a human prostatic carcinoma cell line (PC-3). , 1979, Investigative urology.

[45]  H. Smith.  In vitro properties of epithelial cell lines established from human carcinomas and nonmalignant tissue. , 1979, Journal of the National Cancer Institute.

[46]  E. L. Springer,et al.  Epithelial cell cultures from normal and cancerous human tissues. , 1976, Journal of the National Cancer Institute.

[47]  M. Olivé,et al.  Breast tumor cell lines from pleural effusions. , 1974, Journal of the National Cancer Institute.

[48]  Adriana,et al.  Resistance to Transforming Growth Factor 1 and Activin Due to Reduced Receptor Expression in Human Breast Tumor Cell Lines ’ , 2005 .

[49]  W. Stetler-Stevenson,et al.  Quantitative reverse zymography: analysis of picogram amounts of metalloproteinase inhibitors using gelatinase A and B reverse zymograms. , 1997, Analytical biochemistry.

[50]  S. Rydziel,et al.  Transforming growth factor beta1 inhibits collagenase 3 expression by transcriptional and post-transcriptional mechanisms in osteoblast cultures. , 1997, Journal of cellular physiology.

[51]  T. Yoneda,et al.  Facilitation and suppression of bone metastasis : Skeletal cancer metastasis recent expansion of orthopaedic expertise , 1995 .

[52]  A. Skubitz,et al.  Tumor cell invasion, matrix metalloproteinases, and the dogma. , 1994, Laboratory investigation; a journal of technical methods and pathology.

[53]  L. Bonewald,et al.  Role of transforming growth factor-beta in bone remodeling. , 1990, Clinical orthopaedics and related research.